Compare MP & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MP | PRAX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | 998 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 7.1B |
| IPO Year | 2020 | 2020 |
| Metric | MP | PRAX |
|---|---|---|
| Price | $41.57 | $307.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $75.25 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 5.3M | 323.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $331,952,000.00 | N/A |
| Revenue This Year | $100.51 | N/A |
| Revenue Next Year | $60.41 | $7,758.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 147.15 | N/A |
| 52 Week Low | $37.81 | $37.25 |
| 52 Week High | $100.25 | $366.52 |
| Indicator | MP | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 35.96 | 46.85 |
| Support Level | N/A | $284.87 |
| Resistance Level | $64.62 | $331.51 |
| Average True Range (ATR) | 2.54 | 16.94 |
| MACD | -0.24 | -2.52 |
| Stochastic Oscillator | 27.34 | 35.57 |
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America. The company is also developing a rare earth metal, alloy, and magnet manufacturing facility in Fort Worth, Texas. The company's operations are organized into two reportable segments: Materials and Magnetics.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.